The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis.
Tasnim HasanEllie MedcalfBern-Thomas Nyang'waErica EgiziCatherine BerryMatthew DoddSalah ForaidaMedea GegiaMengchun LiFuad MirzayevHannah MorganIlaria MottaLinh NguyenSamuel SchumacherTim SchlubGreg FoxPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Regimens containing BPaL were relatively well-tolerated when they included a daily linezolid dose of 600mg. These novel regimens promise to improve the tolerability of treatment for MDR/RR-TB.
Keyphrases
- mycobacterium tuberculosis
- methicillin resistant staphylococcus aureus
- systematic review
- multidrug resistant
- open label
- big data
- pulmonary tuberculosis
- drug resistant
- case report
- meta analyses
- double blind
- electronic health record
- randomized controlled trial
- staphylococcus aureus
- clinical trial
- hepatitis c virus
- smoking cessation